Dr. Meera Hameed

Dr. Meera Hameed graduated from Kilpauk Medical College (Madras, India) with an MBBS and went on to a research fellowship and pathology residency at Hahnemann University (Philadelphia, PA). Shen then moved to Memorial Sloan Kettering Cancer Center (New York, NY) for a Fellowship training in oncologic pathology and molecular pathology. Upon completion of her fellowship training, Dr. Hameed became an Assistant Professor in the Department of Pathology at the Albert Einstein College of Medicine. She then moved to the Department of Pathology and Laboratory Medicine at the UMDNJ-New Jersey Medical School (Newark, NJ) where she was promoted through the academic ranks to Professor. In 2009, Dr. Hameed moved to the Department of Pathology at the Memorial Sloan Kettering Cancer Center with an appoint in the Department of Pathology at the Weill-Cornell Medical College. Dr. Hameed is Chief of Surgical Pathology, Co-Director of the Alpert Center for Digital and Computational Pathology, and an active member of the Sarcoma Disease Management Team at Memorial Sloan Kettering Cancer Center. She plays an active role in the training of fellows in oncologic surgical pathology as they rotate through bone and soft tissue pathology. Dr. Hameed is active with several pathology societies and has served as an elected member of the Education Committee for United States and Canadian Academy of Pathology (USCAP) and the Meritorious Award Committee of the American Society of Investigative Pathology. She is also an Associate Editor for The American Journal of Pathology and is a member of the Editorial Board of Modern Pathology.

Dr. Hameed is Board certified in surgical pathology, molecular pathology, and clinical cytogenetics. As a surgical pathologist, Dr. Hameed’s expertise is bone and soft tissue (musculoskeletal) pathology. In this capacity, she works closely with clinical colleagues – including surgeons, radiologists, and medical oncologists – in support of patient care. Dr. Hameed is an Invited Member of the International Skeletal Society – an organization of radiologists, pathologists, and surgeons who meet annually to discuss rare and unusual presentations of the various bone and soft tissue neoplasms. Dr. Hameed serves as course co-director for orthopedic pathology at meetings of the USCAP. As a molecular pathologist, Dr. Hameed keeps abreast of latest developments in the fast-growing field of molecular oncology. As an invited member of the Molecular Oncology Committee of the College of American Pathologists CAP), she serves as the committee member for the sarcoma sub-division and provides expertise on test development and appropriate molecular testing for sarcoma patients. Dr. Hameed’s research involves the study of chromosomal changes and their interpretion related to pathological diagnostic correlations. She specifically explores prognostic markers in bone and soft tissue neoplasms. For example, she has studied expression of markers with therapeutic significance, such as the EGFR family of tyrosine kinases in synovial sarcomas and osteosarcomas.

Dr. Roy Jensen honored by the American Lung Association

The American Lung Association in Kansas & Greater Kansas City presented the prestigious Legacy Award to Dr. Roy A. Jensen. Dr. Jensen, who is also the director of the Kansas Masonic Research Institute, will receive the award for his distinguished commitment to public health and Tobacco 21 policy, his dedication to cancer research and for successfully bringing a National Cancer Institute-designated Cancer Center to the Greater Kansas City community. Dr. Jensen is a FASEB Science Policy Committee member as well as a long-time ASIP member and active on the Research and Science Policy Committee.

See the Press Releases Below:

Lung Association to Honor Dr. Roy Jensen at Drive-in Event

Today, the American Lung Association in Kansas & Greater Kansas City announced that they will present the prestigious Legacy Award to Dr. Roy A. Jensen, director of The University of Kansas Cancer Center. The award will be presented at the Lung Association’s LUNG FORCE Glam on Thursday, May 13 (7pm – 9:30pm) at the Boulevard Drive-in Theatre.

Local Law Firm, Healthcare Partners Invest in Community

Nonprofits are suffering from decreased donations and cancelled fundraisers due to the pandemic, but the American Lung Association in Kansas & Greater Kansas City is breathing a sigh of gratitude today as The Accurso Law Firm and The University of Kansas Health System, along with The University of Kansas Cancer Center, agreed to be the Visionary Sponsors of the Association’s LUNG FORCE Glam on Thursday, May 13 (7pm – 9:30pm) at the Boulevard Drive-in Theatre.

Dr. Lindsey Kennedy

Lindsey Kennedy is an Assistant Research Professor of Medicine and a VA Health Science Specialist at Indiana University School of Medicine and the Richard L. Roudebush VA Medical Center in Indianapolis, IN. She was appointed these titles February of 2021 following her post-doctoral fellowship at Indiana University School of Medicine under the mentorship of Dr. Heather Francis. Her program focuses on the impact of estrogen signaling on the progression of liver damage in autoimmune liver diseases, and the pathological role of angiogenic signaling during cholestasis. She was recently awarded a pilot award from AASLD Foundation, and a Career Development Award from the VA for her work in these areas. Lindsey has been actively involved in ASIP sponsored events since the beginning of her studies in graduate school, and has attended multiple EB and PISA meetings. These engagements have offered her valuable training opportunities and networking abilities, and this year she was awarded the George K. Michalopoulos Junior Faculty Scholar Award, which is excitingly her first faculty award since her appointment. This year she participated in the ASIP Social Ambassador program and hopes to further her efforts in scientific outreach. Her involvement in the ASIP Liver Pathobiology SIG has been a highlight of her career and she is excited to continue attending EB and PISA, and to see the growth of the organization.

Dr. Kelsey McKillip

Dr. McKillip completed a BS in Biology (minor in Chemistry) from Muskingum College (New Concord, OH) in 2009. At Muskingum College, Dr. McKillip held a Science Division Scholarship, a Faculty Scholarship, and a Hodges Research Grant. She then entered graduate school at the University of Cincinnati (Cincinnati, OH) and completed a PhD in Pathobiology and Molecular Medicine in 2014. Dr. McKillip’s dissertation research in the laboratory of Dr. Zhongyun Dong was focused on “anti-cancer implications of small molecule compounds targeting proliferating cell nuclear antigen.” Some of Dr. McKillip’s dissertation research was published in Molecular Pharmacology and Molecular Cancer Therapy. Dr. McKillip was a co-inventor on a patent for “PCNA targeting compounds for cancer therapy” (granted in 2018) that grew from her dissertation research. Dr. McKillip was recognized as Student of the Year in the Pathobiology and Molecular Medicine Graduate Program in 2014, and she was recognized on several other occasions with recognition for excellent research.

In 2015, Dr. McKillip became a Clinical Instructor in the Department of Pathology and Laboratory Medicine at the University of Cincinnati, and she was promoted to Clinical Assistant Professor in 2017. In 2015, Dr. McKillip became the Director of the University of Cincinnati Biorepository, in 2016 she became Technical Director of the Histopathology Core Laboratory, and in 2019 became the Technical Director of the Precision Medicine Laboratory.  This year, Dr. McKillip was awarded the UC College of Medicine Research Service Award in recognition of her dedication and service to the research mission of her institution.  Dr. McKillip also participates in the teaching mission of the University of Cincinnati providing lectures for graduate students on a variety of subjects from “biorepositories and biospecimen research” to “identification of new drugs for cancer therapy.” Dr. McKillip serves as a consultant for the Post-Graduate Hematology/Oncology Translational Training Program which is supported by a T32 grant from the NIH/NCI. Dr. McKillip also participates in teaching of pathology residents (since 2015) from her department, providing lectures related to “biobanking, molecular genetic testing, and solid tumor testing.” Dr. McKillip also teaches and mentors students in the laboratory. To date she has mentored two undergraduates, five graduate students (including 2 Masters and 3 PhD students), and four pathology residents. Dr. McKillip is also extremely active in various Committees at the University of Cincinnati that oversee clinical operations, including the COVID-19 Operations Subcommittee (since 2020). Dr. McKillip also serves on the University of Cincinnati Institutional Review Board (IRB), which is essential to a strong research program.

Dr. McKillip’s more recent research is translational or applied and focused on utilizing the molecular diagnostics laboratory to identify actionable genomic targets in human disease tissue, as well as issues related to biorepositories in research. In recent years, she expanded biorepository support of cancer research programs, including work with a multidisciplinary team of investigators engaged in microbiome research.  In the spring of 2020, she worked with a collaborative team of clinicians and researchers to establish the Cincinnati COVID-19 Repository (CCR), which to date has collected and banked more than 28,000 serum, plasma, and PBMC aliquots for research. For this work, she has been recognized in news articles and other publications, and this resource has been invaluable for enabling research on COVID-19.

Dr. McKillip has been active and engaged with the ASIP since joining in 2017. She is a member of the Research and Science Policy Committee (since 2018) and the Program Committee (since 2018). In 2020, Dr. McKillip was a co-author on a white paper produced by the Research and Science Policy Committee entitled “Return of individual research results: A guide for biomedical researchers utilizing human biospecimens” that was published in The American Journal of Pathology (Sobel. M.E., et al., 2020, Am. J. Pathol. 190:918-933). In 2020, Dr. McKillip was appointed Interim Chair of the Research and Science Policy Committee when that position was vacated by another member. In this role, Dr. McKillip also became a member of the ASIP Council. In early 2021, Dr. McKillip was elected to serve as the Chair of the Research and Science Policy Committee. Her leadership of the Research and Science Policy Committee has been particularly valuable as it is one of the ASIP’s more active committees, meeting monthly and addressing a wide range of issues and opportunities in representation of the membership of the Society. As a member of the Program Committee, Dr. McKillip has been called upon to contribute to the scientific programs for both the ASIP Annual Meeting and the PISA meetings. In 2018, she participated in a round table discussion on “maximizing biospecimen resources” at the PISA 2018 meeting at the University of Michigan. At Experimental Biology 2021, Dr. McKillip gave a short talk on her “alternative academic career” as a pathology PhD in the session entitled “I am an ASIP member and this is my science.”